<DOC>
	<DOCNO>NCT01828177</DOCNO>
	<brief_summary>This 4-arm Phase 2 vehicle-controlled study design ass safety efficacy PDI-320 , individual component , adult subject rosacea .</brief_summary>
	<brief_title>An Evaluation PDI-320 Comparison Its Monads Adults With Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Subject moderate severe papulopustular rosacea least mild erythema mild telangiectasia . Subject willing able apply test article ( ) direct , comply study instruction commit followup visit duration study . If subject woman childbearing potential , must negative urine pregnancy test agree use effective form birth control duration study . Subject pregnant , lactate plan become pregnant study . Subject active dermatological condition face may interfere conduct study . Subject use systemic immunosuppressant within 30 day prior study start . Subject use systemic retinoids within 6 month prior study start . Subject use topical rosacea therapy within 14 day prior study start . Subject laser light therapy face within 3 month study start . Subject currently enrol investigational drug device study . Subject use investigational drug investigational device treatment within 30 day prior first application test article . Subject use vasodilator adrenergic block agent within 6 week study start ( except subject stable dose great 3 month ) . Subject active ocular rosacea and/or blepharitis/meibomianitis require treatment ophthalmologist . Subject previously fail improvement rosacea appropriate use systemic tetracycline family antibiotic use component PDI320 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>PreCision</keyword>
	<keyword>PDI-320</keyword>
	<keyword>Foam</keyword>
</DOC>